DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Patten & Patten Inc. TN

Patten & Patten Inc. TN boosted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 4.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 77,958 shares of the medical device company’s stock after acquiring an additional 3,147 shares during the period. Patten & Patten Inc. TN’s holdings in DexCom were worth $5,324,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in DXCM. Private Trust Co. NA boosted its stake in shares of DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares during the last quarter. Golden State Wealth Management LLC raised its holdings in DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock valued at $27,000 after buying an additional 264 shares during the period. Optiver Holding B.V. purchased a new stake in shares of DexCom during the fourth quarter valued at approximately $33,000. TD Private Client Wealth LLC raised its stake in shares of DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 167 shares during the period. Finally, Larson Financial Group LLC increased its stake in shares of DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after buying an additional 137 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Trading Down 1.4%

Shares of NASDAQ DXCM opened at $85.61 on Thursday. The stock has a market cap of $33.57 billion, a price-to-earnings ratio of 59.87, a PEG ratio of 2.30 and a beta of 1.43. The business has a 50 day simple moving average of $75.64 and a 200 day simple moving average of $78.89. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $120.48. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The company’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.32 EPS. On average, research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Jereme M. Sylvain sold 7,000 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $73.83, for a total transaction of $516,810.00. Following the completion of the transaction, the executive vice president now directly owns 135,482 shares in the company, valued at $10,002,636.06. The trade was a 4.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 6,184 shares of the company’s stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the transaction, the executive vice president now owns 109,621 shares of the company’s stock, valued at $9,329,843.31. The trade was a 5.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 83,110 shares of company stock valued at $6,103,505 over the last 90 days. 0.32% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Piper Sandler dropped their price target on shares of DexCom from $100.00 to $90.00 and set an “overweight” rating for the company in a research note on Friday, May 2nd. Mizuho assumed coverage on DexCom in a research note on Thursday, April 10th. They issued an “outperform” rating and a $85.00 target price on the stock. Barclays lifted their price objective on shares of DexCom from $90.00 to $93.00 and gave the company an “equal weight” rating in a research note on Monday, May 5th. Morgan Stanley boosted their price target on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Finally, Cfra Research upgraded shares of DexCom to a “hold” rating in a research report on Friday, March 21st. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.32.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.